Page 6 - Cipla

Cipla gets approval to market Afrezza insulin inhalation powder in India

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus. By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement. Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections. Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. T

Eli Lilly to launch its obesity drug at competitive price in India in 2025

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

Stocks to Watch, Dec 3: Cipla, Axis Bank, Swiggy, TaMo, Adani Ports, SBI

Stocks to Watch, Dec 3: From Adani Group to Cipla here are few stocks that will be eyed today

Stocks to Watch, Dec 2: HUL, Raymond, SBI, Cipla Titan, Adani Group shares

Stocks to Watch, Dec 2: Here is a list of stocks that will be in focus for today's session

Cipla promoters may sell 1.72% stake worth Rs 2,000 crore via block deal

The floor price for the Cipla share sale has been set at Rs 1,442 per share, reflecting a 6 per cent discount to the current market price

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Stocks to watch, Nov 21: Adani Group stocks, Cipla, UPL, BoB, Tata Tech

Here is a list of stocks that will be in focus from Adani Group stocks to Tata Power

Drug maker Cipla gets 8 observations from USFDA for Bengaluru facility

Drug maker Cipla on Wednesday said the US health regulator has issued eight observations after inspecting its Bengaluru-based plant. The US Food and Drugs Administration (USFDA) conducted an inspection at the company's manufacturing facility in Virgonagar, Bengaluru from November 7- 13, the Mumbai-based based drug maker said in a filing to BSE. On conclusion of the inspection, the company received eight observations in Form 483, it added. The company said it will work closely with the USFDA and remain committed to addressing these observations comprehensively within stipulated time.

Here's why Cipla share price zoomed 10% on October 31; check details

The uptick in Cipla share price came after the United States Food and Drug Administration (USFDA) on Wednesday classified Goa facility as Voluntary Action Indicated (VAI)

Cipla faces challenges of slow growth, drug launch; analysts slash target

Shares of pharmaceutical giant Cipla dipped 5 per cent at Rs 1,403 per share on the NSE in Wednesday's intraday deals

Pharma major Cipla not in the pink of health; growth challenges galore

Brokerages slash target price after subdued Q2 show

Cipla Q2 results: Net profit rises 15% to Rs 1,303 crore, revenue up 5.6%

Cipla eyes growth in the Indian and US markets with upcoming launches

Cipla Q2 results: Net profit up 17%, income from operations at Rs 7,051 cr

Drug major Cipla on Tuesday reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the second quarter ended September 2024, driven by robust sales across markets. The company had reported a net profit of Rs 1,115 crore in the July-September quarter of the last fiscal. Its total income from operations rose to Rs 7,051 crore in the second quarter compared to Rs 6,490 crore in the year-ago period, Cipla said in a regulatory filing. "In Q2 FY25, we recorded a revenue growth of 9 per cent over the last year with a highest-ever EBITDA margin of 26.7 per cent driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said. The company's 'One-India' business was impacted during the quarter due to a changed seasonal pattern. However key chronic therapies in the branded prescription business continued to grow faster than the market, he added. The company's consumer health business grew at a strong 21 per cent year-on-year, Vohra said. "

Cipla drops over 3% ahead of Q2FY25 results; know what analysts expect

Shares of Cipla dropped 3.55 per cent at Rs 1,450 per share on the BSE in Tuesday's intraday trade

Q2 results today: Maruti, Cipla and Adani among 139 firms to post earnings

Q2FY25 company results: Adani Ports, Adani Enterprises, Canara Bank, Muthoot Capital, and SBI Cards and Payment Services will be releasing their second-quarter earnings report on October 29

Cipla Q2 Preview: Analysts expect lukewarm growth in sales, profit

Analysts expect Cipla to register a low single digit rise in the topline and bottomline, with margins being impacted by modest sales in the US and domestic formulations

Cipla, Alkem eye Rs 4,000 crore stake in India's largest stent manufacturer

India's largest stent manufacturer, Sahajanand Medical Technologies is also reportedly exploring a public listing on the domestic market

UBS fears slowdown in India, US pharma markets; gives 'Sell' on 4 stocks

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

MK Hamied steps down as Cipla's Vice Chairman on account of age, health

Drug major Cipla on Tuesday said MK Hamied has resigned as Vice Chairman with effect from October 29 due to age and health. "It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," he said in a letter to the board of directors. The company said the board has also approved the appointment of Kamil Hamied as Non-Executive Director, with effect November 1, 2024. "I am pleased to see that Kamil Hamied will be joining the Board as a Non-Executive Director to maintain continuity while representing the promoter family," MK Hamied said in the letter.

Sun Pharma, Cipla among top picks by Ajit Mishra of Religare Broking

Markets experienced a breather after the recent decline, gaining over a percent, driven by strong global cues.